Search Results - Chowdhury, Swapan
- Showing 1 - 7 results of 7
-
1
-
2
Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT(4) Receptor Agonist by Pusalkar, Sandeepraj, Chowdhury, Swapan K., Czerniak, Richard, Zhu, Xiaochun, Li, Yuexian, Balani, Suresh K., Ramsden, Diane
Published 2022Text -
3
-
4
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours by Moore, Kathleen N, Bauer, Todd M, Falchook, Gerald S, Chowdhury, Swapan, Patel, Chirag, Neuwirth, Rachel, Enke, Aaron, Zohren, Fabian, Patel, Manish R
Published 2018Text -
5
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors by Zhou, Xiaofei, Sedarati, Farhad, Faller, Douglas V., Zhao, Dan, Faessel, Hélène M., Chowdhury, Swapan, Bolleddula, Jayaprakasam, Li, Yuexian, Venkatakrishnan, Karthik, Papai, Zsuzsanna
Published 2020Text -
6
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors by Gupta, Neeraj, Zhang, Steven, Pusalkar, Sandeepraj, Plesescu, Mihaela, Chowdhury, Swapan, Hanley, Michael J., Wang, Bingxia, Xia, Cindy, Zhang, Xiaoquan, Venkatakrishnan, Karthik, Shepard, Dale R.
Published 2017Text -
7
Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury by Wolenski, Francis S., Zhu, Andy Z. X., Johnson, Mike, Yu, Shaoxia, Moriya, Yuu, Ebihara, Takuya, Csizmadia, Vilmos, Grieves, Jessica, Paton, Martin, Liao, Mingxiang, Gemski, Christopher, Pan, Liping, Vakilynejad, Majid, Dragan, Yvonne P., Chowdhury, Swapan K., Kirby, Patrick J.
Published 2017Text